ArticleOncology reports2016
FAM172A modulates apoptosis and proliferation of colon cancer cells via STAT1 binding to its promoter.
Article in Oncology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 17 citations in OpenAlex.
- Nanomaterial-based CT contrast agents and their applications in image-guided therapy.Theranostics · 2023Review
- Dendrimer-modified gold nanorods as a platform for combinational gene therapy and photothermal therapy of tumors.Journal of experimental & clinical cancer research : CR · 2021Article
- CXCL10 Produced by HPV-Positive Cervical Cancer Cells Stimulates Exosomal PDL1 Expression by FibroblastsFrontiers in oncology · 2021Article
- FAM172A affects cell proliferation and apoptosis not by targeting β-tubulin in HepG2 cells.Translational cancer research · 2020Article
- FAM172A inhibits EMT in pancreatic cancer via ERK-MAPK signaling.Biology open · 2020Article
- The Effect of Protein FAM172A on Proliferation in HepG2 Cells and Investigation of the Possible Molecular Mechanism.Analytical cellular pathology (Amsterdam) · 2019Article
- Article
- FAM172A expression in circulating tumor cells for prediction of high-risk subgroups of colorectal cancer.OncoTargets and therapy · 2017Article
Corrections and comments
- Retraction · 2023-04-13Duplication of/in Image · Investigation by Third Party · Paper Mill · · see also: https://pubpeer.com/publications/0FF3BCF6083F78917273E98E385FB6
- Retracted
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In our previous study, low expression of FAM172A protein was found in colon cancer tissues. This research was planned to explore the functions of FAM172A gene and examine the mechanisms of its transcriptional regulation. Firstly, flow cytometry showed that FAM172A inhibited proliferation and promoted apoptosis and differentiation of colon cancer cells. Then through continuous truncation, we identified the minimal functional promoter region of FAM172A. Subsequently, we found that STAT1, as a transcription factor, could bind to the minimal FAM172A promoter, as evaluated using Chromatin immunoprecipitation (ChIP) and Electrophoreticmobility shift assay (EMSA). The results of Western blot analysis and qRT-PCR indicated that STAT1 was able to upregulate the expression of FAM172A. Our results showed that FAM172A could suppress proliferation of colon cancer cells, and STAT1 could bind to the minimum promoter region of FAM172A and upregulated the expression of FAM172A. These results may provide advanced insights into the functions of FAM172A and its regulatory mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.